ClinicalTrials.gg
CompletedNCT02170116Updated Jun 23, 2014

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

A Phase 1 interventional study of BIBR 1048 MS dose 1 and BIBR 1048 MS dose 2 in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-23.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The objective of this study was to assess safety, pharmacokinetics and the effect of BIBR 953 ZW on coagulation parameters of BIBR 953 ZW after oral single doses of the prodrug, BIBR 1048 MS, in healthy male subjects. This was the first administration of this substance to humans.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects as determined by results of screening
  • Signed written in accordance with Good Clinical Practice (GCP) and local legislation
  • Age >= 18 and \<= 45 years
  • Broca >= - 20 % and \<= + 20 %

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance
  • History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
  • Chronic or relevant acute infections
  • History of

    • allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic disease
    • cerebral bleeding (e.g. after a car accident)
    • commotion cerebri
  • Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
  • Use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial
  • Participation in another trial with an drug within 2 months prior to administration or during trial
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation within 1 month prior to administration or during the trial
  • Excessive physical activities within 5 days prior to administration or during the trial
  • Any laboratory value outside the clinically accepted reference range
  • History of any familial bleeding disorder
  • \< 150000/µl
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
40 participants (actual)

Study arms

  • Experimental
    BIBR 1048 MS dose 1

    Drug: BIBR 1048 MS dose 1

  • Experimental
    BIBR 1048 MS dose 2

    Drug: BIBR 1048 MS dose 2

  • Experimental
    BIBR 1048 MS dose 3

    Drug: BIBR 1048 MS dose 3

  • Experimental
    BIBR 1048 MS dose 4

    Drug: BIBR 1048 MS dose 4

  • Experimental
    BIBR 1048 MS dose 5

    Drug: BIBR 1048 MS dose 5

  • Placebo comparator
    Placebo

    Drug: Placebo to BIBR 1048 MS

06

What researchers measure

Primary outcomes

  1. Changes from baseline in prothrombin time (PT) (International Normalised Ratio (INR))

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration

  2. Changes from baseline in activated partial thromboplastin time (aPTT)

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration

Secondary outcomes

  1. Peak (maximum) plasma concentration (Cmax) of BIBR 953 ZW

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  2. time to reach the peak plasma concentration (tmax ) of BIBR 953 ZW

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  3. AUC0-12 h - Area under the plasma concentration-time curve of BIBR 953 ZW from 0 to 12 h

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  4. Area under the plasma concentration-time curve (AUC0-infinity) of BIBR 953 ZW from 0 to infinity

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  5. Area under the plasma concentration-time curve of BIBR 953 ZW (AUCtf -infinity) from tf (last time point when measured plasma concentration) to infinity expressed as % of AUC0-infinity

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  6. Terminal half-life(t1/2 ) of BIBR 953 ZW derived from non-compartmental analysis

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  7. Total mean residence time (MRTtot ) of BIBR 953 ZW

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  8. Total clearance (CLtot /f ) of BIBR 953 ZW after oral administration

    Time frame: 24 hours after administration

  9. Volume of distribution (Vz/f ) of BIBR 953 ZW during terminal phase after oral administration

    Time frame: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  10. Changes from baseline in Pulse rate

    Time frame: up to day 3

  11. Changes from baseline in Systolic and diastolic blood pressure

    Time frame: up to day 3

  12. Occurrence of Adverse events

    Time frame: up to day 3

  13. Changes from baseline in Ecarin Clotting Time (ECT)

    Time frame: up to day 3

  14. Changes from baseline in thrombin inhibition test time

    Time frame: up to day 3

  15. Changes from baseline in thrombin time

    Time frame: up to day 3

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1998 and a primary completion of Dec 1998. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Nov 1998
Primary completionActual
Dec 1998
Last update
Jun 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02170116
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Nov 1998
Primary completion
Dec 1998
Last update
Jun 23, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion